Clinical stage biotech company, PharmAust (ASX:PAA), announced that its wholly-owned subsidiary Epichem is ready to accelerate growth after fully paying off its debt liability. Image: Getty
PharmAust’s wholly owned subsidiary Epichem pays off debt in full, ready to accelerate its growth phase
PharmAust is set to benefit from Epichem’s debt repayment with an expected improvement to the bottom line, as it begins to leverage the state-of-the-art laboratories in Technology Park, WA.
Clinical stage biotech company, PharmAust (ASX:PAA), announced that its wholly-owned subsidiary Epichem is ready to accelerate growth after fully paying off its debt liability.
Perth-based Epichem today paid the debt on time, after using the funds for a major laboratory expansion in Technology Park, WA.
The company had initially sought an export loan from Export Finance Australia (EFA) in 2015, with assistance from parent company, PharmAust.
The $750k loan was used to build a state-of-the-art laboratory on new premises, and was paid back to the EFA in 2019 when the first stage of the lab was completed.
Epichem subsequently built a second laboratory at the Technology Park site to keep up with customer demand, and had borrowed another $460k from the EFA, again with assistance from PharmAust.
The labs have world class equipment and expertise in synthetic and medicinal chemistry to support Epichem’s drug discovery projects, and for the cost-effective synthesis of its drug analogue libraries and intermediates.
These new labs have also provided jobs for an additional 20 employees, making Epichem one of Australia’s top employers of PhD educated individuals in the medical science and technology SME sector.
The loan repayment also means that Epichem will save on interest and principal, and this will be reflected in an improvement to its bottom line margins going forward.
“It is a major accomplishment for the company,” says PharmAust chairman, Dr Roger Aston.
“Epichem’s global competitiveness has been boosted with the investment in cutting-edge laboratories, growth in workforce and the recently acquired OHD technology.”
“With the EFA loan repaid and positive revenue trajectory, we look forward to further growth at Epichem,” Aston added.
Epichem’s capabilities
Epichem has been delivering products in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for 17 years.
The company has expanded its chemistry expertise to now include material science applications to the Energy, Resources, Waste, Recycling and AgTech sectors.
Epichem said it has completed building the flow reactor using the benchtop Oxidative Hydrothermal Dissolution (OHD) technology.
The flow reactor is a world-first, with the potential to turn a wide range of waste and biomass feedstock into valuable energy products, and is located at the state of the art laboratory at Technology Park.
PharmAust says that potential revenue streams from this technology could come from the removal of organic waste, its conversion to valuable end user products, as well as reduction of landfill.
Data shows that bioplastics will grow into a $28 billion market in five years time, while the bio-ethanol market is expected to double to $65 billion in five years time.
PharmAust’s clinical trials
Apart from Epichem, PharmAust itself has had a productive quarter in its efforts to commercialise lead drug, monepantel (MPL).
PharmAust is now contacting leading global animal healthcare companies to seek partners to co-develop and commercialise MPL for treatment of veterinary cancers.
The company is currently preparing for several other clinical trials, which include a Phase II Human Cancer Trial to study MPL in diseases such as pancreatic cancer or oesophageal cancer.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.